Chien-Ying Chang

Title: Chien-Ying Chang: Innovator in ASCT2-Binding Molecules

Introduction

Chien-Ying Chang is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of ASCT2-binding molecules. With a total of 3 patents to his name, his work has the potential to impact cancer treatment and diagnostics.

Latest Patents

One of Chien-Ying Chang's latest patents focuses on binding molecules specific for ASCT2 and their uses. This disclosure provides ASCT2-binding molecules, such as anti-ASCT2 antibodies and antigen-binding fragments. In certain aspects, these molecules are conjugated to cytotoxic drugs, forming ASCT2 antibody-drug conjugates (ADCs). The anti-ASCT2 antibodies can be hybridoma-derived murine monoclonal antibodies or humanized versions. These binding molecules specifically target cells expressing ASCT2 and can be internalized into these cells. The patent also outlines compositions and methods for diagnosing and treating diseases characterized by ASCT2 overexpression, including certain types of cancer. In particular, it provides methods for treating cancer using ASCT2 ADCs.

Career Highlights

Chien-Ying Chang is currently associated with MedImmune Limited, where he continues to advance his research and innovations. His work is pivotal in the development of targeted therapies that could revolutionize cancer treatment.

Collaborations

Chien-Ying Chang has collaborated with notable colleagues, including Partha S Chowdhury and Nabendu Pore. These collaborations enhance the research environment and contribute to the advancement of their shared goals in biotechnology.

Conclusion

Chien-Ying Chang's innovative work in ASCT2-binding molecules showcases his commitment to improving cancer treatment and diagnostics. His contributions are significant in the ongoing battle against cancer, and his patents reflect a promising future in medical research.